Page last updated: 2024-11-05

antimony pentafluoride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

antimony pentafluoride: often mixed with acids to form super acids [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24557
CHEBI ID193146
MeSH IDM0521779

Synonyms (27)

Synonym
einecs 232-021-8
hsdb 442
antimony (v) fluoride
antimony pentafluoride
antimony(v) fluoride
antimony(v) fluoride, 99.99% trace metals basis
antimony(v) fluoride on graphite, extent of labeling: 50 wt. % loading
antimony(v) fluoride, 99%
pentafluoridoantimony
7783-70-2
antimon(v)-fluorid
CHEBI:193146
pentakis(fluoranyl)-$l^{5}-stibane
A839231
pentafluorostiborane
unii-6c93r71vrf
antimony pentafluoride [un1732] [corrosive]
AKOS016015580
FT-0622431
antimony-penta-fluoride
VBVBHWZYQGJZLR-UHFFFAOYSA-I
mfcd00011219
sbf5
antimony(v) fluoride compound with graphite
DTXSID00893075
Q411381
pentafluoro-lambda5-stibane
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Lewis acidA molecular entity that is an electron-pair acceptor and therefore able to form a covalent bond with an electron-pair donor (Lewis base), thereby producing a Lewis adduct.
NMR solventA solvent used in nuclear magnetic resonance (NMR) spectroscopy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
antimony molecular entity
inorganic fluoride salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (41.67)29.6817
2010's7 (58.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]